Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 992

1.

Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance.

Schaetti C, Hutubessy R, Ali SM, Pach A, Weiss MG, Chaignat CL, Khatib AM.

BMC Public Health. 2009 Apr 7;9:99. doi: 10.1186/1471-2458-9-99.

2.

Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar.

Schaetti C, Chaignat CL, Hutubessy R, Khatib AM, Ali SM, Schindler C, Weiss MG.

Hum Vaccin. 2011 Dec;7(12):1299-308. doi: 10.4161/hv.7.12.18012. Epub 2011 Dec 1.

PMID:
22108036
3.

Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.

Sundaram N, Schaetti C, Merten S, Schindler C, Ali SM, Nyambedha EO, Lapika B, Chaignat CL, Hutubessy R, Weiss MG.

BMC Public Health. 2016 Jan 14;16:36. doi: 10.1186/s12889-016-2710-0.

4.

The case for reactive mass oral cholera vaccinations.

Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, Lopez AL, Jiddawi MS, Clemens JD, von Seidlein L.

PLoS Negl Trop Dis. 2011 Jan 25;5(1):e952. doi: 10.1371/journal.pntd.0000952.

5.

Improving community coverage of oral cholera mass vaccination campaigns: lessons learned in Zanzibar.

Schaetti C, Ali SM, Chaignat CL, Khatib AM, Hutubessy R, Weiss MG.

PLoS One. 2012;7(7):e41527. doi: 10.1371/journal.pone.0041527. Epub 2012 Jul 23.

7.

Social and cultural features of cholera and shigellosis in peri-urban and rural communities of Zanzibar.

Schaetti C, Khatib AM, Ali SM, Hutubessy R, Chaignat CL, Weiss MG.

BMC Infect Dis. 2010 Nov 26;10:339. doi: 10.1186/1471-2334-10-339.

8.

Mass vaccination with a two-dose oral cholera vaccine in a refugee camp.

Legros D, Paquet C, Perea W, Marty I, Mugisha NK, Royer H, Neira M, Ivanoff B.

Bull World Health Organ. 1999;77(10):837-42.

9.

Cholera vaccines for the developing world.

Lopez AL, Clemens JD, Deen J, Jodar L.

Hum Vaccin. 2008 Mar-Apr;4(2):165-9. Epub 2007 Oct 7. Review.

PMID:
18414029
10.

Social and cultural determinants of oral cholera vaccine uptake in Zanzibar.

Schaetti C, Ali SM, Hutubessy R, Khatib AM, Chaignat CL, Weiss MG.

Hum Vaccin Immunother. 2012 Sep;8(9):1223-9. doi: 10.4161/hv.20901. Epub 2012 Aug 16.

11.

Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo.

Merten S, Schaetti C, Manianga C, Lapika B, Chaignat CL, Hutubessy R, Weiss MG.

BMC Public Health. 2013 Jan 22;13:60. doi: 10.1186/1471-2458-13-60.

12.

Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.

Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J.

Lancet Infect Dis. 2012 Nov;12(11):837-44. doi: 10.1016/S1473-3099(12)70196-2. Epub 2012 Sep 4.

PMID:
22954655
13.

Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.

Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R.

PLoS Negl Trop Dis. 2012;6(10):e1844. doi: 10.1371/journal.pntd.0001844. Epub 2012 Oct 4.

14.

Control of diarrhoeal diseases.

Martinez CA, Barua D, Merson MH.

World Health Stat Q. 1988;41(2):74-81.

PMID:
3176516
15.

First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF.

PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2465. doi: 10.1371/journal.pntd.0002465. eCollection 2013.

16.

Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam.

Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, Do GC, Naficy A, Nguyen TK, Acosta CJ, Deen JL, Clemens JD, Dang DT.

J Health Popul Nutr. 2003 Dec;21(4):304-8.

PMID:
15043004
17.

Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.

Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF.

PLoS Negl Trop Dis. 2014 Feb 6;8(2):e2629. doi: 10.1371/journal.pntd.0002629. eCollection 2014 Feb.

18.

What older people want: evidence from a study of remote Scottish communities.

King G, Farmer J.

Rural Remote Health. 2009 Apr-Jun;9(2):1166. Epub 2009 Jun 24.

19.

A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.

Cookson ST, Stamboulian D, Demonte J, Quero L, Martinez de Arquiza C, Aleman A, Lepetic A, Levine MM.

Int J Epidemiol. 1997 Feb;26(1):212-9.

PMID:
9126522
20.

Lot quality survey: an appealing method for rapid evaluation of vaccine coverage in developing countries - experience in Turkey.

Cakir B, Uner S, Temel F, Akin L.

BMC Public Health. 2008 Jul 16;8:240. doi: 10.1186/1471-2458-8-240.

Supplemental Content

Support Center